Monash University, Melbourne, Victoria, Australia.
Ann Intern Med. 2010 Dec 7;153(11):728-35. doi: 10.7326/0003-4819-153-11-201012070-00006.
Although the accuracy of B-type natriuretic peptide (BNP) testing for diagnosing acute decompensated heart failure has been extensively evaluated, the effect of this test on clinical outcomes remains unclear.
To investigate whether BNP testing of patients presenting with acute dyspnea in the emergency department leads to fewer admissions, shorter length of stay, and improved short-term survival compared with usual care without BNP testing.
Two reviewers searched Ovid MEDLINE and EMBASE, without language restrictions, to identify pertinent studies published from January 1996 to July 2010.
Randomized, controlled trials that compared BNP testing to diagnose heart failure with routine care in patients presenting with acute dyspnea and information about 1 or more of the following outcomes: mortality, admission, or length of hospital stay.
Two authors independently reviewed articles, extracted data, and assessed quality and risk for bias of studies.
Five trials conducted in 5 countries and involving 2513 patients met inclusion criteria. Study settings had differing emergency department staffing models and used various BNP testing protocols. The pooled estimate of effect of BNP testing on all-cause mortality had wide confidence bounds and was inconclusive (odds ratio, 0.96 [95% CI, 0.65 to 1.41]). Admission rates decreased in the tested group compared with the control group (odds ratio, 0.82 [CI, 0.67 to 1.01]), although this finding was not statistically significant. Length of hospital and critical care unit stay were both modestly reduced in the tested group compared with the control group, with a mean difference of -1.22 days (CI, -2.31 to -0.14 day) and -0.56 day (CI, -1.06 to -0.05 day), respectively.
Few relevant trials were studied. Patients included in the trials and the settings in which trials were conducted were heterogeneous.
B-type natriuretic peptide testing in the emergency department for patients presenting with acute dyspnea decreased length hospital of stay by about 1 day and possibly reduced admission rates but did not conclusively affect hospital mortality rates.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
尽管 B 型利钠肽(BNP)检测用于诊断急性失代偿性心力衰竭的准确性已经得到广泛评估,但该检测对临床结局的影响尚不清楚。
研究与不进行 BNP 检测的常规护理相比,对急诊科出现急性呼吸困难的患者进行 BNP 检测是否可导致更少的入院、更短的住院时间和改善短期存活率。
两名审查员在没有语言限制的情况下,通过 Ovid MEDLINE 和 EMBASE 搜索了相关研究,这些研究发表于 1996 年 1 月至 2010 年 7 月。
比较 BNP 检测与常规护理诊断呼吸困难患者心力衰竭的随机对照试验,以及以下 1 个或多个结果的信息:死亡率、入院或住院时间。
两名作者独立审查文章,提取数据,并评估研究的质量和偏倚风险。
5 项在 5 个国家进行的试验纳入了 2513 名患者,符合纳入标准。研究地点的急诊科人员配备模式不同,并且使用了不同的 BNP 检测方案。BNP 检测对全因死亡率影响的汇总估计值置信区间较宽,结果不确定(比值比,0.96[95%置信区间,0.65 至 1.41])。与对照组相比,检测组的入院率降低(比值比,0.82[95%置信区间,0.67 至 1.01]),尽管这一发现无统计学意义。与对照组相比,检测组的住院和重症监护病房住院时间均略有缩短,平均差异为-1.22 天(95%置信区间,-2.31 至-0.14 天)和-0.56 天(95%置信区间,-1.06 至-0.05 天)。
研究的相关试验较少。纳入试验的患者和试验进行的环境存在异质性。
对急诊科出现急性呼吸困难的患者进行 B 型利钠肽检测可使住院时间缩短约 1 天,并可能降低入院率,但不能确定是否会影响住院死亡率。
澳大利亚墨尔本莫纳什大学流行病学和预防医学系。